Literature DB >> 22926517

miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling.

C A Gebeshuber1, J Martinez.   

Abstract

Dysregulation of micro RNAs is crucially implicated in tumorigenesis. We detected downregulation of miR-100 in breast cancer cells, leading to an upregulation of the proliferation- and survival-promoting oncogene insulin-like growth factor (IGF) 2. Stable overexpression of miR-100 strongly reduced IGF2 expression and inhibited tumor growth. In invasive human breast tumors, miR-100 was reduced about fourfold as compared with benign patient samples, whereas IGF2 was strongly enhanced. MiR-100 has also been shown to suppress other proteins of the IGF/mammalian target of rapamycin (mTOR) signaling cascade in different human tumors. Our results reveal miR-100 as a context-dependent master regulator of the IGF/mTOR pathway and a potential target for therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926517     DOI: 10.1038/onc.2012.372

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN.

Authors:  Lei Shen; Xiao-Dong Chen; Yao-Hui Zhang
Journal:  Tumour Biol       Date:  2013-10-15

2.  Role of miR-100 in the radioresistance of colorectal cancer cells.

Authors:  Xiao-Dong Yang; Xiao-Hui Xu; Shu-Yu Zhang; Yong Wu; Chun-Gen Xing; Gan Ru; Hong-Tao Xu; Jian-Ping Cao
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

3.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Authors:  William Damsky; Goran Micevic; Katrina Meeth; Viswanathan Muthusamy; David P Curley; Manjula Santhanakrishnan; Ildiko Erdelyi; James T Platt; Laura Huang; Nicholas Theodosakis; M Raza Zaidi; Scott Tighe; Michael A Davies; David Dankort; Martin McMahon; Glenn Merlino; Nabeel Bardeesy; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

Review 4.  Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.

Authors:  Chu Qin; Ru-Yi Huang; Zhao-Xia Wang
Journal:  Tumour Biol       Date:  2015-03-05

5.  MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61.

Authors:  Jianhua Huang; Kanda Gao; Jian Lin; Qiugen Wang
Journal:  Tumour Biol       Date:  2013-12-10

Review 6.  Noncoding RNAs in breast cancer.

Authors:  Pang-Kuo Lo; Benjamin Wolfson; Xipeng Zhou; Nadire Duru; Ramkishore Gernapudi; Qun Zhou
Journal:  Brief Funct Genomics       Date:  2015-12-18       Impact factor: 4.241

7.  MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells.

Authors:  Katayoon Pakravan; Sadegh Babashah; Majid Sadeghizadeh; Seyed Javad Mowla; Majid Mossahebi-Mohammadi; Farangis Ataei; Nasim Dana; Mohammad Javan
Journal:  Cell Oncol (Dordr)       Date:  2017-07-24       Impact factor: 6.730

8.  Predicting associations between microRNAs and target genes in breast cancer by bioinformatics analyses.

Authors:  Tianying Zheng; Xing Zhang; Yonggang Wang; Xiucui Yu
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

9.  Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma.

Authors:  Guihua Wang; Lianhua Chen; Junsong Meng; Min Chen; Ling Zhuang; Liqin Zhang
Journal:  Int Urol Nephrol       Date:  2013-02-03       Impact factor: 2.370

10.  MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development.

Authors:  Lu Deng; Li Shang; Shoumin Bai; Ji Chen; Xueyan He; Rachel Martin-Trevino; Shanshan Chen; Xiao-Yan Li; Xiaojie Meng; Bin Yu; Xiaolin Wang; Yajing Liu; Sean P McDermott; Alexa E Ariazi; Christophe Ginestier; Ingrid Ibarra; Jia Ke; Tahra Luther; Shawn G Clouthier; Liang Xu; Ge Shan; Erwei Song; Herui Yao; Gregory J Hannon; Stephen J Weiss; Max S Wicha; Suling Liu
Journal:  Cancer Res       Date:  2014-09-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.